Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00171145 | A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. | PHASE3 | COMPLETED | 445 | — | — | Apr 1, 2004 | Dec 1, 2004 | Jan 23, 2008 | 1 | United States |
| NCT00170755 | A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder | PHASE3 | COMPLETED | 718 | — | — | Apr 1, 2002 | Jan 1, 2005 | Jan 17, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Darifenacin |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Darifenacin | DRUG | Darifenacin 15 mg tablets once daily |
| Placebo | DRUG | Placebo tablets once daily |
Inclusion Criteria: * Three symptoms of OAB (urge incontinence, frequency and urgency) for at least six months prior to Visit 2. * Patients capable of independent toileting and able of independently completing the patient diary. Exclusion Criteria: * Patients in whom the use of anticholinergic dr...